Genmab — Maj 2019
-
Prospektet beskriver meget godt
hvad der kan ske ved manglende partnerships https://www.sec.gov/Archives/edgar/data/1434265/000104746919003334/a2238822zf-1.htmhttps://www.sec.gov/Archives/edgar/data/1434265/000104746919003334/a2238822zf-1.htm -
-
We intend to use the net proceeds from the offering as follows:to advance tisotumab vedotin to commercialization in recurrent and/or metastatic cervical cancer, to progress tisotumab vedotin in other solid tumor indications and to continue building our commercial capabilities in connection with the potential future approval of tisotumab vedotin; and to fund drug discovery efforts, to further our development of existing and new technol
-
This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. We cannot predict with certainty all of the particular uses of the net proceeds of this offering or the amounts that we will actually spend on the uses set forth above.
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind